• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《临床糖尿病、肥胖症及代谢性疾病进展》特刊社论

Editorial for the Special Issue "Advances in Clinical Diabetes, Obesity, and Metabolic Diseases".

作者信息

Ohshiro Yuzuru, Yagi Kunimasa, Maeno Yasuhiro

机构信息

Department of Internal Medicine, Omoromachi Medical Center, 1-3-1 Uenoya, Naha 900-0011, Okinawa, Japan.

School of Medicine, Kanazawa Medical University, 1-1 Daigaku, Uchinada 920-0293, Ishikawa, Japan.

出版信息

Medicina (Kaunas). 2025 Mar 26;61(4):595. doi: 10.3390/medicina61040595.

DOI:10.3390/medicina61040595
PMID:40282884
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12028995/
Abstract

Diabetes, obesity, and metabolic diseases are posing significant challenges to healthcare systems globally [...].

摘要

糖尿病、肥胖症和代谢性疾病正在给全球医疗系统带来重大挑战[...]。

相似文献

1
Editorial for the Special Issue "Advances in Clinical Diabetes, Obesity, and Metabolic Diseases".《临床糖尿病、肥胖症及代谢性疾病进展》特刊社论
Medicina (Kaunas). 2025 Mar 26;61(4):595. doi: 10.3390/medicina61040595.
2
[A plea for a better nutritional management of cancer patients].
Cancer Radiother. 1999 May-Jun;3(3):197-9. doi: 10.1016/s1278-3218(99)80051-1.
3
COVID-19 and metabolic disease: mechanisms and clinical management.新型冠状病毒肺炎与代谢性疾病：机制与临床管理。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798. doi: 10.1016/S2213-8587(21)00244-8. Epub 2021 Oct 4.
4
Diabetes Metabolism: Research and Reviews--Chinese Diabetes Society special issue: a small but encouraging step toward the successful control of diabetes in China.《糖尿病代谢：研究与评论》——中华医学会糖尿病学分会专刊：在中国成功控制糖尿病方面迈出的虽小但令人鼓舞的一步。
Diabetes Metab Res Rev. 2014 Sep;30(6):445-6. doi: 10.1002/dmrr.2579.
5
[Measures to prevent the progress of glucose tolerance disorders. I].[预防糖耐量异常进展的措施。I]
Probl Endokrinol (Mosk). 1972 Sep-Oct;18(5):3-6.
6
Metabolism, Obesity, and Diabetes Mellitus.代谢、肥胖和糖尿病。
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):e166-e174. doi: 10.1161/ATVBAHA.119.312005. Epub 2019 Jun 26.
7
Editorial overview: Endocrine and metabolic diseases: Waistline weapons: new therapeutic avenues for the treatment of obesity and metabolic disease.社论综述：内分泌和代谢疾病：腰围武器：治疗肥胖和代谢疾病的新治疗途径。
Curr Opin Pharmacol. 2015 Dec;25:iv-vi. doi: 10.1016/j.coph.2015.10.005. Epub 2015 Nov 10.
8
Dietary fat, dyspepsia, diarrhoea, and diabetes.膳食脂肪、消化不良、腹泻与糖尿病。
Br J Surg. 1972 Sep;59(9):669-95. doi: 10.1002/bjs.1800590902.
9
[Tenth and eleventh meetings of national internal Endocrinology, Diabetes and Metabolic Diseases: summaries].[全国内分泌、糖尿病及代谢疾病第十次和第十一次会议纪要]
Ann Endocrinol (Paris). 2010 Feb;71(1):28-9. doi: 10.1016/j.ando.2010.01.001.
10
Research advances in metabolism 2016.2016年新陈代谢研究进展
Metabolism. 2017 Feb;67:41-53. doi: 10.1016/j.metabol.2016.11.001. Epub 2016 Nov 6.

本文引用的文献

1
Artificial intelligence in the management of metabolic disorders: a comprehensive review.人工智能在代谢紊乱管理中的应用：综述
J Endocrinol Invest. 2025 Feb 19. doi: 10.1007/s40618-025-02548-x.
2
Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.
Expert Rev Endocrinol Metab. 2025 Mar;20(2):163-168. doi: 10.1080/17446651.2025.2462100. Epub 2025 Feb 7.
3
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.胰高血糖素样肽-1受体激动剂对心血管事件和危险因素的疗效及安全性比较：一项综述与网状Meta分析
Diabetes Obes Metab. 2025 Apr;27(4):1735-1751. doi: 10.1111/dom.16228. Epub 2025 Feb 5.
4
Neurometabolic Profile in Obese Patients: A Cerebral Multi-Voxel Magnetic Resonance Spectroscopy Study.肥胖患者的神经代谢特征：一项基于磁共振波谱多体素的研究。
Medicina (Kaunas). 2024 Nov 16;60(11):1880. doi: 10.3390/medicina60111880.
5
Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?为何在无2型糖尿病的肥胖成年人中，胰高糖素样肽-1（GLP-1）激动剂联合葡萄糖依赖性促胰岛素多肽（GIP）和/或胰高血糖素原（GCG）激动剂比单独使用GLP-1激动剂具有更强的减重效果？
Diabetes Obes Metab. 2025 Mar;27(3):1079-1095. doi: 10.1111/dom.16106. Epub 2024 Nov 26.
6
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.评估新型肠促胰岛素疗法对2型糖尿病心血管结局的影响：一项早期系统评价。
Pharmaceuticals (Basel). 2024 Oct 3;17(10):1322. doi: 10.3390/ph17101322.
7
Regular Physical Activity in the Prevention of Post-Transplant Diabetes Mellitus in Patients after Kidney Transplantation.定期身体活动可预防肾移植后患者发生移植后糖尿病。
Medicina (Kaunas). 2024 Jul 26;60(8):1210. doi: 10.3390/medicina60081210.
8
Effects of Age and Biological Age-Determining Factors on Telomere Length in Type 2 Diabetes Mellitus Patients.年龄和生物学年龄决定因素对 2 型糖尿病患者端粒长度的影响。
Medicina (Kaunas). 2024 Apr 24;60(5):698. doi: 10.3390/medicina60050698.
9
Improved Glycemic Control through Robot-Assisted Remote Interview for Outpatients with Type 2 Diabetes: A Pilot Study.通过机器人辅助远程访谈改善 2 型糖尿病门诊患者的血糖控制：一项试点研究。
Medicina (Kaunas). 2024 Feb 15;60(2):329. doi: 10.3390/medicina60020329.
10
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.每周一次伊克多昔与每日一次甘精 U100 在无前期胰岛素的 2 型糖尿病中的应用比较。
N Engl J Med. 2023 Jul 27;389(4):297-308. doi: 10.1056/NEJMoa2303208. Epub 2023 Jun 24.